--Guidance for cash usage in 2H08 is $14M (excluding any financing transactions or new partnership deals).
--3Q08 will benefit from the initial $3M payment from Ovation (provided that the deal actually closes).
--4Q08 will benefit from the next $2M payment from Ovation, assuming that the FDA accepts the ATryn BLA for review during the quarter.
--3Q08/4Q08 will benefit from a $3M reimbursement by LFB for the companies’ joint venture. (This is in addition to the $3M reimbursement from LFB during 2Q08.)
Let’s talk biotech! “If your beloved drug candidate sounds too good to be true, it probably is.”
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.